ASCO血液肿瘤研究精粹

2016ASCO血液肿瘤研究进展良医汇-肿瘤资讯Slide1PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide2PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide3PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide4PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide5PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide6PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide7PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide8PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide9PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide10PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide11PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide12PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide13PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide14PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide15PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide16PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide17PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide18PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide19PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide20PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide21PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide22PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide23PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide24PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide25PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide26PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide27PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide28PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide29PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide30PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide31PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide32PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingSlide33PresentedByHerveAvet-Loiseauat2016ASCOAnnualMeetingPETAdaptedStrategiesInTreatmentOfAdvancedHodgkinLymphomaPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingAdvancedHodgkinLymphoma<br/>ChemotherapywithABVDPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingAdvancedHodgkinLymphoma<br/>ChemotherapywithBEACOPPescalatedPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide4PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide5PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide6PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingPredictivevalueofinterimPETvariesaccordingtocriteriausedPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingPETResponseAdaptedStrategiesPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingInterimPETadaptedstrategiesinadvancedHLPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingPETResponseAdaptedStrategies<br/><br/>StartwithABVDx2:escalate/de-escalatetherapybasedonPET2PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide11PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingResults:USIntergroupTrial(S0816)PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide13PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide14PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide15PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingRATHLResults:PET-2NEG<br/>parisonofToxicityofABVDvsAVDPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingRATHLResults:PET2negativePresentedByRanjanaAdvaniat2016ASCOAnnualMeetingToxicityofBEACOPPesc:Grade3-4EventsPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide19PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide20PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide21PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingInterimPET-CTresponseadaptedstrategies<br/><br/>StartwithBEACOPPescx2:escalate/de-escalatetherapybasedonPET2PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide23PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingResultsAHL2011:Adverseevents≥grade3PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingResultsAHL2011:PFSaccordingtotreatmentarmPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingAHL2011:PFSaccordingtoPETresultPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingRisk-stratifiedandFDG-PET-responseAdaptedTherapyInAdvancedHodgkinLymphoma:IsraeliH2studyPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingRadiotherapyinAdvancedStageHL<br/>RoleofPETPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingGHSGHD15trialinadvanced-stageHL<br/>PETguidedradiotherapypostBEACOPPesc<br/>PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingResults:HD15TrialPET-GuidedRTPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingRadiotherapyinAdvancedStageHodgkinLymphoma:BCCAexperience<br/>NegativePET-ScanFollowingTreatmentwithABVDPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide32PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide33PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide34PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSummaryOfRecentInterimPETAdaptedStudiesPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide36PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSlide37PresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSummaryOfRecentInterimPETAdaptedStudiesPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingSummaryPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingFuture:MolecularMarkersToDefineRiskPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingAdvancedHodgkinLymphomaPresentedByRanjanaAdvaniat2016ASCOAnnualMeetingNewTargetsinMultipleMyelomaPresentedBySagarLonialat2016ASCOAnnualMeetingMyelomaDrugDevelopmentPresentedBySagarLonialat2016ASCOAnnualMeetingWhoarethePlayersPresentedBySagarLonialat2016ASCOAnnualMeetingIxazomib(MLN9708)PresentedBySagarLonialat2016ASCOAnnualMeetingIxazomib:twiceweeklydosingPresentedBySagarLonialat2016ASCOAnnualMeetingIxazomib:onceweeklydosingPresentedBySagarLonialat2016ASCOAnnualMeetingTOURMALINE-MM1:Phase3studyofweeklyoralixazomibpluslenalidomide-dexamethasonePresentedBySagarLonialat2016ASCOAnnualMeetingFinalPFSanalysis:<br/>Asignificant,35%improvementinPFSwith<br/>IRdvsplacebo-RdPresentedBySagarLonialat2016ASCOAnnualMeetingOuesbycytogeneticriskgroupPresentedBySagarLonialat2016ASCOAnnualMeetingHowdoesixazomibfitintocurrenttreatmentsPresentedBySagarLonialat2016ASCOAnnualMeetingSlide11PresentedBySagarLonialat2016ASCOAnnualMeetingPanoramaTrialValidatesPreclinicalDataPresentedBySagarLonialat2016ASCOAnnualMeetingInAbsenceofBiomarker,OtherPredictorsofBenefitPresentedBySagarLonialat2016ASCOAnnualMeetingAreThereBetterPartners?PresentedBySagarLonialat2016ASCOAnnualMeetingWhatisImmuneTherapy?PresentedBySagarLonialat2016ASCOAnnualMeetingTargetsforMoABsinMMPresentedBySagarLonialat2016ASCOAnnualMeetingSLAMF7PresenceandFunctionPresentedBySagarLonialat2016ASCOAnnualMeetingElotuzumabworksviaadualmechanismofactionbybothdirectlyactivatingNaturalKillerCellsandthroughantibody-dependentcell-mediatedcytotoxicity(ADCC)tocausetargetedMyelomacelldeathPresentedBySagarLonialat2016ASCOAnnualMeetingELOQUENT-2StudyDesignPresentedBySagarLonialat2016ASCOAnnualMeetingProgression-FreeSurvivalPresentedBySagarLonialat2016ASCOAnnualMeetingInterimOverallSurvivalPresentedBySagarLonialat2016ASCOAnnualMeetingTimetoNextTreatmentPresentedBySagarLonialat2016ASCOAnnualMeetingProgression-FreeSurvivalbyTumorResponsePresentedBySagarLonialat2016ASCOAnnualMeetingImprovementinHighRiskPatientswithNovelMechanismofAction:MOABsare‘RiskAgnostic’PresentedBySagarLonialat2016ASCOAnnualMeetingInfusionReactionsPresentedBySagarLonialat2016ASCOAnnualMeetingHowdoesEloFitintocurrenttreatmentsPresentedBySagarLonialat2016ASCOAnnualMeetingDARA:MechanismsofActionPresentedBySagarLonialat2016ASCOAnnualMeetingGEN501:FirstinHumanStudyPresentedBySagarLonialat2016ASCOAnnualMeetingPhase2StudyofDaratumumab(DARA)inPatientswith≥3LinesofPriorTherapyorDoubleRefractoryMultipleMyeloma:54767414MMY2002(Sirius)*PresentedBySagarLonialat2016ASCOAnnualMeetingInfusion-relatedReactions(IRRs)PresentedBySagarLonialat2016ASCOAnnualMeetingIstheeffectofIMIDsPresentinLenRefractoryPatients?PresentedBySagarLonialat2016ASCOAnnualMeetingDifferentialEffectstheSameTargetPresentedBySagarLonialat2016ASCOAnnualMeetingOverallResponseRatePresentedBySagarLonialat2016ASCOAnnualMeetingWheredoesDarafitintocurrenttreatments?PresentedBySagarLonialat2016ASCOAnnualMeetingNewAgentsindevelopmentPresentedBySagarLonialat2016ASCOAnnualMeetingOngoingACY-1215inbinationwithLenalidomideandDexamethasoneorBortezomibPresentedBySagarLonialat2016ASCOAnnualMeetingXPO1(CRM1)istheExclusiveNuclearExporterofMajorTumorSuppressorProteinsPresentedBySagarLonialat2016ASCOAnnualMeetingMultipleMyeloma:Selinexor±Dex(Phase1)<br/>PresentedBySagarLonialat2016ASCOAnnualMeetingSlide39PresentedBySagarLonialat2016ASCOAnnualMeetingSlide40PresentedBySagarLonialat2016ASCOAnnualMeetingPersonalizedMedicineandBiology<br/>ExpressionoftargetscriticaltoourbesttargetsPresentedBySagarLonialat2016ASCOAnnualMeetingMyelomacellsmaintainaplasmacellphenotype.<br/>Arethesecharacteristicsalsoessentialformyelomacellsurvival?PresentedBySagarLonialat2016ASCOAnnualMeetingSlide43PresentedBySagarLonialat2016ASCOAnnualMeetingTaoofMyelomaTherapyPresentedBySagarLonialat2016ASCOAnnualMeetingHowdoesPersonalizedorPrecisionMedicineApply?PresentedBySagarLonialat2016ASCOAnnualMeetingSlide46PresentedBySagarLonialat2016ASCOAnnualMeetingSlide47PresentedBySagarLonialat2016ASCOAnnualMeetingFutureDirectionsPresentedBySagarLonialat2016ASCOAnnualMeetingSlide49PresentedBySagarLonialat2016ASCOAnnualMeetingUpdatedDatafromaDoseFindingPhaseIITrial<br/>ofSingleAgentIsatuximab(Anti-CD38mAb)<br/>inRelapsed/RefractoryMultipleMyelomaPresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide2PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide3PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide4PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide5PresentedByJoshuaRichterat2016ASCOAnnualMeeting<br/>PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide7PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide8PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide9PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide10PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide11PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide12PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide13PresentedByJoshuaRichterat2016ASCOAnnualMeetingSlide14PresentedByJoshuaRichterat2016ASCOAnnualMeetingIsatuximabInfusionDurationPresentedByJoshuaRichterat2016ASCOAnnualMeetingSummaryPresentedByJoshuaRichterat2016ASCOAnnualMeetingAcknowledgmentsPresentedByJoshuaRichterat2016ASCOAnnualMeetingPhaseI/IITrial:<br/>Ixazomib,Pomalidomide,DexamethasoneinRelapsed/RefractoryMultipleMyeloma<br/>InitialResults<br/>PresentedByAmritaKrishnanat2016ASCOAnnualMeetingBackgroundPresentedByAmritaKrishnanat2016ASCOAnnualMeetingBackgroundPresentedByAmritaKrishnanat2016ASCOAnnualMeetingMethodsPresentedByAmritaKrishnanat2016ASCOAnnualMeetingSlide5PresentedByAmritaKrishnanat2016ASCOAnnualMeetingSlide6PresentedByAmritaKrishnanat2016ASCOAnnualMeetingSlide7PresentedByAmritaKrishnanat2016ASCOAnnualMeetingAdverseeventsPresentedByAmritaKrishnanat2016ASCOAnnualMeetingDose-limitingtoxicitiesPresentedByAmritaKrishnanat2016ASCOAnnualMeetingConclusionsPresentedByAmritaKrishnanat2016ASCOAnnualMeetingAcknowledgmentsPresentedByAmritaKrishnanat2016ASCOAnnualMeetingAcknowledgmentsPresentedByAmritaKrishnanat2016ASCOAnnualMeetingSlide13PresentedByAmritaKrishnanat2016ASCOAnnualMeetingDLTdefinitionPresentedByAmritaKrishnanat2016ASCOAnnualMeetingDLTdefinitionPresentedByAmritaKrishnanat2016ASCOAnnualMeetingEvolvingchangesinM-protein(M),quantitativeinvolvedimmunoglobulin(Ig),andhemoglobin(Hb)toidentifypatients(pts)withultrahigh-risksmolderingmultiplemyeloma(UHR-SMM)PresentedByPrafulRaviat2016ASCOAnnualMeetingBackgroundPresentedByPrafulRaviat2016ASCOAnnualMeetingHigh-RiskSmolderingMyelomaPresentedByPrafulRaviat2016ASCOAnnualMeetingEvolvingPatterninSmolderingMyelomaPresentedByPrafulRaviat2016ASCOAnnualMeetingSlide5PresentedByPrafulRaviat2016ASCOAnnualMeetingObjectivesPresentedByPrafulRaviat2016ASCOAnnualMeetingMethodsPresentedByPrafulRaviat2016ASCOAnnualMeetingMethodsPresentedByPrafulRaviat2016ASCOAnnualMeetingBaselineCharacteristicsPresentedByPrafulRaviat2016ASCOAnnualMeetingEvolvingChangePresentedByPrafulRaviat2016ASCOAnnualMeetingPredictorsofEarly(≤2yrs)ProgressionPresentedByPrafulRaviat2016ASCOAnnualMeetingSlide12PresentedByPrafulRaviat2016ASCOAnnualMeetingUltraHigh-RiskSmolderingMyelomaPresentedByPrafulRaviat2016ASCOAnnualMeetingSensitivityAnalysesPresentedByPrafulRaviat2016ASCOAnnualMeetingConclusionsPresentedByPrafulRaviat2016ASCOAnnualMeetingAcknowledgementsPresentedByPrafulRaviat2016ASCOAnnualMeetingUpfrontautologousstemcelltransplantation(ASCT)versusnovelagent-basedtherapyforMultipleMyeloma(MM):arandomizedphase3studyoftheEuropeanMyelomaNetwork(EMN02/HO95MMtrial)PresentedByMicheleCavoat2016ASCOAnnualMeetingBackgroundPresentedByMicheleCavoat2016ASCOAnnualMeetingBackground.2PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide4PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide5PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide6PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide7PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide8PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide9PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide10PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide11PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide12PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide13PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide14PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide15PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide16PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide17PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide18PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide19PresentedByMicheleCavoat2016ASCOAnnualMeetingSlide20PresentedByMicheleCavoat2016ASCOAnnualMeetingNewTargetsinMultipleMyelomaPresentedBySagarLonialat2016ASCOAnnualMeetingMyelomaDrugDevelopmentPresentedBySagarLonialat2016ASCOAnnualMeetingWhoarethePlayersPresentedBySagarLonialat2016ASCOAnnualMeetingIxazomib(MLN9708)PresentedBySagarLonialat2016ASCOAnnualMeetingIxazomib:twiceweeklydosingPresentedBySagarLonialat2016ASCOAnnualMeetingIxazomib:onceweeklydosingPresentedBySagarLonialat2016ASCOAnnualMeetingTOURMALINE-MM1:Phase3studyofweeklyoralixazomibpluslenalidomide-dexamethasonePresentedBySagarLonialat2016ASCOAnnualMeetingFinalPFSanalysis:<br/>Asignificant,35%improvementinPFSwith<br/>IRdvsplacebo-RdPresentedBySagarLonialat2016ASCOAnnualMeetingOuesbycytogeneticriskgroupPresentedBySagarLonialat2016ASCOAnnualMeetingHowdoesixazomibfitintocurrenttreatmentsPresentedBySagarLonialat2016ASCOAnnualMeetingSlide11PresentedBySagarLonialat2016ASCOAnnualMeetingPanoramaTrialValidatesPreclinicalDataPresentedBySagarLonialat2016ASCOAnnualMeetingInAbsenceofBiomarker,OtherPredictorsofBenefitPresentedBySagarLonialat2016ASCOAnnualMeetingAreThereBetterPartners?PresentedBySagarLonialat2016ASCOAnnualMeetingWhatisImmuneTherapy?PresentedBySagarLonialat2016ASCOAnnualMeetingTargetsforMoABsinMMPresentedBySagarLonialat2016ASCOAnnualMeetingSLAMF7PresenceandFunctionPresentedBySagarLonialat2016ASCOAnnualMeetingElotuzumabworksviaadualmechanismofactionbybothdirectlyactivatingNaturalKillerCellsandthroughantibody-dependentcell-mediatedcytotoxicity(ADCC)tocausetargetedMyelomacelldeathPresentedBySagarLonialat2016ASCOAnnualMeetingELOQUENT-2StudyDesignPresentedBySagarLonialat2016ASCOAnnualMeetingProgression-FreeSurvivalPresentedBySagarLonialat2016ASCOAnnualMeetingInterimOverallSurvivalPresentedBySagarLonialat2016ASCOAnnualMeetingTimetoNextTreatmentPresentedBySagarLonialat2016ASCOAnnualMeetingProgression-FreeSurvivalbyTumorResponsePresentedBySagarLonialat2016ASCOAnnualMeetingImprovementinHighRiskPatientswithNovelMechanismofAction:MOABsare‘RiskAgnostic’PresentedBySagarLonialat2016ASCOAnnualMeetingInfusionReactionsPresentedBySagarLonialat2016ASCOAnnualMeetingHowdoesEloFitintocurrenttreatmentsPresentedBySagarLonialat2016ASCOAnnualMeetingDARA:MechanismsofActionPresentedBySagarLonialat2016ASCOAnnualMeetingGEN501:FirstinHumanStudyPresentedBySagarLonialat2016ASCOAnnualMeetingPhase2StudyofDaratumumab(DARA)inPatientswith≥3LinesofPriorTherapyorDoubleRefractoryMultipleMyeloma:54767414MMY2002(Sirius)*PresentedBySagarLonialat2016ASCOAnnualMeetingInfusion-relatedReactions(IRRs)PresentedBySagarLonialat2016ASCOAnnualMeetingIstheeffectofIMIDsPresentinLenRefractoryPatients?PresentedBySagarLonialat2016ASCOAnnualMeetingDifferentialEffectstheSameTargetPresentedBySagarLonialat2016ASCOAnnualMeetingOverallResponseRatePresentedBySagarLonialat2016ASCOAnnualMeetingWheredoesDarafitintocurrenttreatments?PresentedBySagarLonialat2016ASCOAnnualMeetingNewAgentsindevelopmentPresentedBySagarLonialat2016ASCOAnnualMeetingOngoingACY-1215inbinationwithLenalidomideandDexamethasoneorBortezomibPresentedBySagarLonialat2016ASCOAnnualMeetingXPO1(CRM1)istheExclusiveNuclearExporterofMajorTumorSuppressorProteinsPresentedBySagarLonialat2016ASCOAnnualMeetingMultipleMyeloma:Selinexor±Dex(Phase1)<br/>PresentedBySagarLonialat2016ASCOAnnualMeetingSlide39PresentedBySagarLonialat2016ASCOAnnualMeetingSlide40PresentedBySagarLonialat2016ASCOAnnualMeetingPersonalizedMedicineandBiology<br/>ExpressionoftargetscriticaltoourbesttargetsPresentedBySagarLonialat2016ASCOAnnualMeetingMyelomacellsmaintainaplasmacellphenotype.<br/>Arethesecharacteristicsalsoessentialformyelomacellsurvival?PresentedBySagarLonialat2016ASCOAnnualMeetingSlide43PresentedBySagarLonialat2016ASCOAnnualMeetingTaoofMyelomaTherapyPresentedBySagarLonialat2016ASCOAnnualMeetingHowdoesPersonalizedorPrecisionMedicineApply?PresentedBySagarLonialat2016ASCOAnnualMeetingSlide46PresentedBySagarLonialat2016ASCOAnnualMeetingSlide47PresentedBySagarLonialat2016ASCOAnnualMeetingFutureDirectionsPresentedBySagarLonialat2016ASCOAnnualMeetingSlide49PresentedBySagarLonialat2016ASCOAnnualMeetingSlide1PresentedByMarthaLacyat2016ASCOAnnualMeetingIxazomib(MLN9708)PresentedByMarthaLacyat2016ASCOAnnualMeetingIxazomibbinationsPresentedByMarthaLacyat2016ASCOAnnualMeetingIxazomib-alkylatorbinationsPresentedByMarthaLacyat2016ASCOAnnualMeetingTrialdesignPresentedByMarthaLacyat2016ASCOAnnualMeetingTrialobjectivesPresentedByMarthaLacyat2016ASCOAnnualMeetingInclusioncriteriaPresentedByMarthaLacyat2016ASCOAnnualMeetingExclusioncriteriaPresentedByMarthaLacyat2016ASCOAnnualMeetingTreatmentPresentedByMarthaLacyat2016ASCOAnnualMeetingAssessmentsPresentedByMarthaLacyat2016ASCOAnnualMeetingStatisticaldesignPresentedByMarthaLacyat2016ASCOAnnualMeetingPatientcharacteristicsPresentedByMarthaLacyat2016ASCOAnnualMeetingPatientfollowupPresentedByMarthaLacyat2016ASCOAnnualMeetingEfficacyPresentedByMarthaLacyat2016ASCOAnnualMeetingResponsebycyclePresentedByMarthaLacyat2016ASCOAnnualMeetingSurvivalouesPresentedByMarthaLacyat2016ASCOAnnualMeetingDosereductionsandtolerabilityPresentedByMarthaLacyat2016ASCOAnnualMeetingPharmacokineticsPresentedByMarthaLacyat2016ASCOAnnualMeetingOveralltoxicityprofilePresentedByMarthaLacyat2016ASCOAnnualMeetingmontoxicitiesPresentedByMarthaLacyat2016ASCOAnnualMeetingNeurotoxicityScorePresentedByMarthaLacyat2016ASCOAnnualMeetingConclusionsPresentedByMarthaLacyat2016ASCOAnnualMeetingMyelomaGroupatMayoPresentedByMarthaLacyat2016ASCOAnnualMeetingAPhaseIITrialofABVDfollowedbyBrentuximabVedotinConsolidationTherapyinLimitedStageNon-bulkyHodgkinLymphoma(LCCC1115)PresentedByStevenParkat2016ASCOAnnualMeetingSlide2PresentedByStevenParkat2016ASCOAnnualMeetingSlide3PresentedByStevenParkat2016ASCOAnnualMeetingSlide4PresentedByStevenParkat2016ASCOAnnualMeetingSlide5PresentedByStevenParkat2016ASCOAnnualMeetingSlide6PresentedByStevenParkat2016ASCOAnnualMeetingSlide7PresentedByStevenParkat2016ASCOAnnualMeetingSlide8PresentedByStevenParkat2016ASCOAnnualMeetingSlide9PresentedByStevenParkat2016ASCOAnnualMeetingSlide10PresentedByStevenParkat2016ASCOAnnualMeetingSlide11PresentedByStevenParkat2016ASCOAnnualMeetingSlide12PresentedByStevenParkat2016ASCOAnnualMeetingSlide13PresentedByStevenParkat2016ASCOAnnualMeetingSlide14PresentedByStevenParkat2016ASCOAnnualMeetingSlide15PresentedByStevenParkat2016ASCOAnnualMeetingSlide16PresentedByStevenParkat2016ASCOAnnualMeetingSlide17PresentedByStevenParkat2016ASCOAnnualMeetingSlide18PresentedByStevenParkat2016ASCOAnnualMeetingSlide1PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide2PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide3PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide4PresentedByAndrewEvensat2016ASCOAnnualMeetingUntreatedHighRiskFollicularLymphoma:E2408StudySchemaPresentedByAndrewEvensat2016ASCOAnnualMeetingSlide6PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide7PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide8PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide9PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide10PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide11PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide12PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide13PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide14PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide15PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide16PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide17PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide18PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide19PresentedByAndrewEvensat2016ASCOAnnualMeetingBack-UpSlidesPresentedByAndrewEvensat2016ASCOAnnualMeetingSlide21PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide22PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide23PresentedByAndrewEvensat2016ASCOAnnualMeetingSlide24PresentedByAndrewEvensat2016ASCOAnnualMeetingPILLAR-2:ARandomized,Double-Blind,Placebo-Controlled,Phase3StudyofAdjuvantEverolimusinPatientsWithPoor-RiskDiffuseLargeB-CellLymphomaWhoHadAchievedpleteRemissionWithRituximabbinedChemotherapyPresentedByThomasWitzigat2016ASCOAnnualMeetingDisclosurePresentedByThomasWitzigat2016ASCOAnnualMeetingBackgroundtoUnderstandingthePILLAR-2TrialPresentedByThomasWitzigat2016ASCOAnnualMeetingEvent-freeSurvivalWithR-CHOPinDLBCLPresentedByThomasWitzigat2016ASCOAnnualMeetingWhatElseWasKnownin2008?PresentedByThomasWitzigat2016ASCOAnnualMeetingPILLAR-2StudyDesign:AdjuvantEverolimusPresentedByThomasWitzigat2016ASCOAnnualMeetingStudyTimelineandStatisticalMethodsPresentedByThomasWitzigat2016ASCOAnnualMeetingSlide8PresentedByThomasWitzigat2016ASCOAnnualMeetingSlide9PresentedByThomasWitzigat2016ASCOAnnualMeetingSlide10PresentedByThomasWitzigat2016ASCOAnnualMeetingDisease-FreeSurvivalPresentedByThomasWitzigat2016ASCOAnnualMeetingDisease-FreeSurvivalPresentedByThomasWitzigat2016ASCOAnnualMeetingOverallSurvivalPresentedByThomasWitzigat2016ASCOAnnualMeetingDFSSubgroupExploratoryAnalysis:<br/>TrendFavoringEverolimusinSomeSubgroupsPresentedByThomasWitzigat2016ASCOAnnualMeetingDFSSubgroupEx